S 3427 · 117th Congress 2021–2023, ended

Neuroscience Center of Excellence Act of 2021

Latest action · Dec 16, 2021 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S9263-9264)

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedDec 16, 2021
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Neuroscience Center of Excellence Act of 2021

This bill requires the Food and Drug Administration (FDA) to establish the Neuroscience Center of Excellence to address neuroscience diseases and disorders (e.g., addiction, Alzheimer's disease, and psychotic disorders).

The center must carry out various activities, including (1) coordinating with FDA programs that focus on certain areas, such as drug evaluation; (2) convening periodic public meetings to engage with stakeholders to address challenges associated with developing medical products for neuroscience diseases and disorders; (3) establishing a program to facilitate the collection and systemic use of patient experience data to develop such medical products; and (4) convening a public meeting to discuss how to promote equity and the inclusion of traditionally underrepresented populations in the development of such medical products.

The FDA must take actions related to these issues, such as issuing final guidance with recommendations on the collection and use of patient experience data for developing such medical products.

The Government Accountability Office must report to Congress a study that (1) reviews the participation of traditionally underrepresented populations in clinical trials for such medical products, and (2) provides recommendations for improving the participation of these populations.

Cosponsors 1

Members who signed on, in the order they did. All signed on Dec 16, 2021.

SeatCosponsorSigned on
D-NMBen Ray LujánOriginalDec 16, 2021

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateHealth, Education, Labor, and Pensions Committee
Referred Dec 16, 2021

Actions 2

Everything that happened, newest first.

  1. Dec 16, 2021Introduced in Senate
  2. Dec 16, 2021Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S9263-9264)

In the Congressional Record 1

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
SenateDebate and remarks S9263Susan M. Collins R-MEDec 16, 2021

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to authorize the Secretary of Health and Human Services to establish a Neuroscience Center of Excellence.
Short Title(s) as Introduced
Neuroscience Center of Excellence Act of 2021

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Dec 16, 2021Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.